Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

UBS Downgrades Boston Scientific to 'Neutral'

UBS Financial downgraded Boston Scientific (BSX) to neutral from buy.

Analyst Dave Lothson says the stock has appreciated 170% since the start of 2002, when the TAXUS drug-eluting coronary stent system first became a factor in the company's stock performance. He notes the key drivers of the shares have been the attainment of key legal, clinical, regulatory, and foreign market milestones.

With the U.S. launch of TAXUS about to arrive, he thinks the TAXUS phase of the company's share performance is coming to an end. He expects TAXUS to be hugely successful, driving earnings per share to over $3.00 in 2004. However, beyond that, he says visibility for earnings growth becomes murky.

blog comments powered by Disqus